leisure time -WSS

leisure time

author：leisure time 2025-10-02 18:05:38 - browse：9431

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Indictment alleges Trump's ex

WSS

eGenesis tests gene

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Biden administration begins canceling student loan debt for 804,000 borrowers

Parkinson’s finding may lead to tests and, someday, treatments

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

Francis Collins on trust in science and how Covid communications failed

Walensky prepares to leave CDC — and Congress — behind

AI generated plenty of interest at JPM but not a lot of trust

At least 13 dead in Texas as scorching temps continue

Novo Nordisk touts Wegovy study, but still struggling with supply

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Hospitals are dialing back on venture capital investing

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Timeline: How the deadly wildfires took over Maui day by day

Wikipedia

The tragedy of Johnson & Johnson’s Covid vaccine

Judge sides with young activists in first

Treatments for cramps don't cut it. Why aren't there better options?

Timeline: How the deadly wildfires took over Maui day by day

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

FDA clears AI tool for detecting skin cancer

hotspot

hotspot

hotspot

focus